Blueprint Genetics accepted into the Tekes NIY program

Published on December 12, 2013

We are happy to announce that Blueprint Genetics has been accepted into the NIY program of Tekes (The Finnish National Technology Agency). The program has two phases that enables us to withdraw up to one million euros in subvention when challenging objectives are met. The idea of…

Read more

Blueprint Genetics – Ready for 2014!

Published on December 9, 2013

In June 2013 Blueprint Genetics launched 10 comprehensive diagnostic NGS panels for hereditary cardiovascular diseases. Since then hundreds of clinical samples have been successfully analyzed and interpreted. Thanks to our proprietary sequencing technology (OS-Seq) and bioinformatics pipeline we have been able to increase the quality of analysis, lower the costs…

Read more

A Finnish company enters international markets with world class genetics technology

Published on June 12, 2013

Press release 12 June 2013 Blueprint Genetics has launched a new genetic testing technology for professional use in hospitals. The gene sequencing technology is based on Stanford University research and can effectively analyse rare hereditary human diseases. The company started its operations in 2012 in Helsinki. The tests of Blueprint…

Read more

Suomalainen yhtiö tarjoaa kansainvälisille markkinoille huipputason geeniteknologiaa

Published on June 12, 2013

Lehdistötiedote 12.6.2013 Blueprint Genetics Oy on aloittanut uuteen teknologiaan perustuvien geenitestien tarjoamisen ammattikäyttöön sairaaloille. Yhtiön teknologian perustana on alun perin Stanfordin yliopistossa kehitetty ns. sekvensointimenetelmä, jonka avulla voidaan tehokkaasti tunnistaa tauteihin liittyviä ihmisen perimän muutoksia. Yhtiö aloitti toimintansa vuonna 2012 Helsingin Meilahdessa. Blueprint Geneticsin testit mahdollistavat vaikeisiin perinnöllisiin tauteihin liittyvien…

Read more

New Blueprint Website Launched!

Published on May 30, 2013

Blueprint Genetics is a new genetic diagnostics company that is based in Helsinki, Finland. The company started its operations in 2012 by setting up a laboratory for applying a targeted sequencing method called Oligonucleotide-Selective Sequencing (OS-Seq™)* for rare diseases diagnostics. We are now launching first ten products, all of which…

Read more

Media contact

Juulia Simonen

Communication manager

+358 50 305 9018

Subscribe to our releases

Get our latest press releases.